Biolase and Sartorius are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Biolase has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500.
No comments:
Post a Comment